Plain-English translation of NCT06808984 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called to see if it can help reduce agitation and aggressive behavior in people who have Alzheimer's disease. Agitation is a common and distressing symptom in Alzheimer's patients, and this study wants to know if this medication is safe and whether it actually works better than a placebo (an inactive pill). The medication works by affecting certain brain chemicals that may be involved in causing agitation.
Many people with Alzheimer's disease experience agitation and aggression, which can be difficult for both patients and their caregivers. Current treatment options are limited, so researchers are testing this medication to see if it offers a new, safer way to help manage these symptoms.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be randomly assigned to receive either the new medication at one of two doses or a placebo pill, and you won't know which one you're getting. You'll take the medication by mouth regularly and visit the study site for check-ups where doctors and nurses will monitor how you're doing, assess your agitation levels, and watch for any side effects. The study involves about 120 participants across multiple locations, and the researchers will carefully track your safety and whether the medication helps reduce your agitation symptoms.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
United States